Wegovy as a Medical Treatment: Separating Fact from the Noise

The biggest misconception: Wegovy is just a diet drug for people who don't try hard enough

This is the myth worth correcting first, because it colours everything else. Obesity is a chronic condition with documented hormonal, genetic and neurological drivers, a position the NHS, NICE and the Royal College of Physicians all endorse. Wegovy does not work by boosting motivation or imposing a stricter diet. Semaglutide binds to GLP-1 receptors in the hypothalamus, the part of the brain that regulates hunger, and in the gut, where it slows gastric emptying. The result is that many people feel genuinely less hungry and full sooner, not because they are trying harder, but because a biological signal has changed.

That distinction matters clinically. When the STEP 1 trial ran for 68 weeks, participants on semaglutide 2.4mg lost an average of around 15% of body weight alongside lifestyle support, a reduction that, in people with obesity, translates to meaningful reductions in blood pressure, joint load and cardiovascular risk markers. The trial is published in the New England Journal of Medicine and remains the anchor evidence for Wegovy's MHRA authorisation. Weight loss at that scale is not achievable by willpower alone in most people, which is precisely why medicine is part of the picture for some.

None of this means Wegovy suits everyone, or that it replaces dietary change and activity. The licence specifically requires it to be used alongside both. But the framing of it as a laziness aid is not supported by the biology or the trial data, and it leads people to dismiss a legitimate medical option or feel shame for considering it.

What Wegovy's medical licence in the UK actually covers, and what it does not

The MHRA authorised semaglutide under the brand name Wegovy for weight management in UK adults with a BMI of 30 or above, or a BMI between 27 and 29.9 alongside at least one weight-related health condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

The treatment follows a titration schedule: it starts at a low dose and is increased by a prescriber over several months, reaching a 2.4mg weekly maintenance dose. In April 2026 the MHRA also approved a higher 7.2mg maintenance dose and a dedicated single-dose pen for that strength, for adults with a BMI of 30 or above. You can read more about Wegovy's dosing pathway and how the medicine works on our Wegovy overview page.

What the licence does not cover: Wegovy is not approved for cosmetic weight loss, for use in under-18s, or during pregnancy, breastfeeding, or when trying to conceive. Ozempic contains the same active ingredient but carries a separate licence for type 2 diabetes, it is not interchangeable with Wegovy for weight management purposes, and the MHRA is clear that GLP-1 medicines should not be used for quick or cosmetic purposes. If you are exploring semaglutide more broadly, understanding what Wegovy is called in medical and clinical contexts is one of the first things to get clear before comparing products or prescriptions.

NHS access, NICE criteria and what the private route looks like

NICE recommends Wegovy (TA875) for use within specialist weight management services, for a maximum of two years, in adults with a BMI of 35 or above and at least one weight-related comorbidity. Ethnic-background thresholds are generally 2.5 kg/m² lower. That is a narrower population than the full licensed group, and NHS access through those specialist services typically involves a waiting list. The NICE guidance also specifies that treatment should be stopped if weight loss is less than 5% after six months on the maintenance dose.

For people who do not meet NHS criteria, or who prefer not to wait, a private prescription route through a regulated UK online pharmacy is the legal alternative. That route still requires a genuine clinical consultation, a prescriber reviews your health history, weight, medications and any contraindications before a prescription is issued. The GPhC pharmacy register lets you verify any online pharmacy before you use it; this is the most reliable check available to a UK patient.

Costs in the private market vary by provider and dose. If you want an honest breakdown of what private Wegovy treatment typically involves financially, our Wegovy pricing guide walks through what to expect and what headline prices often leave out. At nume, our prescribers review every consultation personally, you can read about the clinical team on our clinical team page. It is also worth knowing that some patients encounter semaglutide supplied under the Deus Medical brand, so understanding how that differs from licensed Wegovy can help you ask the right questions of any provider. The weight-loss treatment overview sets out the full range of options we support.

Side effects: what is common, what is serious, and when to act

The most frequently reported side effects of Wegovy are gastrointestinal: nausea, constipation, diarrhoea, indigestion and burping. These tend to be most noticeable when starting treatment or after a dose increase and often settle within the first week or two. Taking the injection with food or at a time of day when rest is possible can help some people manage the early weeks.

Less common but more serious effects require prompt attention. Pancreatitis (inflammation of the pancreas) is an infrequent but known risk. Severe stomach pain that spreads to the back, with or without vomiting, should be treated as a medical emergency. The MHRA highlighted this risk specifically in a Drug Safety Update for GLP-1 medicines issued in January 2026. Gallbladder symptoms, signs of a serious allergic reaction and, in people with diabetes, retinopathy changes are also listed in the prescribing information. If you have seen semaglutide marketed through medical spas or aesthetic clinics offering semaglutide treatments, it is important to understand that those settings carry different oversight standards and the same serious risks still apply.

Patients can report any suspected side effects using the MHRA's Yellow Card scheme, and this includes reporting medicines that look suspect or were purchased from an unverified source. If you have questions about side effects before starting treatment, our FAQs page covers common concerns, and our aftercare team is available seven days a week through the contact page.

Ready to find out whether Wegovy might be appropriate for your situation? Speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.